ArticleACR open rheumatology2024
Rheumatology Patients' Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar.
Chiara Gasteiger et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it